References
- Busse WW, Lemanske RF Jr. Asthma. N. Engl. J. Med. 344(5), 350–362 (2001).
- Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat. Rev. Drug Discov. 11(12), 958–972 (2012).
- Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat. Immunol. 12(1), 21–27 (2011).
- Haworth O, Cernadas M, Levy BD. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. J. Immunol. 186(11), 6129–6135 (2011).
- Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36(3), 451–463 (2012).
- Klein Wolterink RG, Kleinjan A, van Nimwegen M et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur. J. Immunol. 42(5), 1106–1116 (2012).
- Mjösberg JM, Trifari S, Crellin NK et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTh2 and CD161. Nat. Immunol. 12(11), 1055–1062 (2011).
- Barnig C, Cernadas M, Dutile S et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci. Transl. Med. 5(174), 174ra26 (2013).
- Henson PM. Dampening inflammation. Nat. Immunol. 6(12), 1179–1181 (2005).
- Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat. Rev. Immunol. 8(5), 349–361 (2008).
- Levy BD, De Sanctis GT, Devchand PR et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. 8(9), 1018–1023 (2002).
- Lee TH, Crea AE, Gant V et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4, D4, and E4 in the bronchoalveolar lavage fluids obtained from patients with selected pulmonary diseases. Am. Rev. Respir. Dis. 141(6), 1453–1458 (1990).
- Christie PE, Spur BW, Lee TH. The effects of lipoxin A4 on airway responses in asthmatic subjects. Am. Rev. Respir. Dis. 145(6), 1281–1284 (1992).
- Wu SH, Chen XQ, Liu B, Wu HJ, Dong L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br. J. Dermatol. 168(1), 172–178 (2013).
- Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E; Severe Asthma Research Program, National Heart, Lung, and Blood Institute. Diminished lipoxin biosynthesis in severe asthma. Am. J. Respir. Crit. Care Med. 172(7), 824–830 (2005).
- Planagumà A, Kazani S, Marigowda G et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am. J. Respir. Crit. Care Med. 178(6), 574–582 (2008).
- Sanak M, Levy BD, Clish CB et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur. Respir. J. 16(1), 44–49 (2000).